Jefferies analyst Roger Song maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report) yesterday and set a price target of $79.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Roger Song has given his Buy rating due to a combination of factors that highlight the potential of Structure Therapeutics, Inc. Sponsored ADR. The company is poised for a catalyst-rich second half of the year, with significant developments expected in their clinical trials. Two Phase 2b readouts are anticipated in the fourth quarter, and the initiation of the amylin first-in-human study is expected by year-end. These milestones are crucial as they could demonstrate the efficacy and safety of their compounds, particularly the ‘1290 compound, which shows promise in differentiating from competitors.
Furthermore, the company is strategically preparing for Phase 3 trials by ensuring manufacturing readiness and exploring strategic partnerships for commercialization. The ongoing development of their small molecule pipeline, including the ACCG-2671 and other compounds targeting obesity and related diseases, also contributes to the positive outlook. With a cash runway extending to 2027, the company is well-positioned to advance its clinical programs and capitalize on emerging opportunities, which supports the Buy rating given by Roger Song.
According to TipRanks, Song is an analyst with an average return of -20.6% and a 28.14% success rate. Song covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, United Therapeutics, and TG Therapeutics.
In another report released on June 3, Piper Sandler also maintained a Buy rating on the stock with a $93.00 price target.